News
ENTX
3.230
+0.31%
0.010
Entera Bio files to sell 134.8M ordinary shares for holders
TipRanks · 20h ago
Entera Bio appoints new chief medical officer
TipRanks · 4d ago
Weekly Report: what happened at ENTX last week (0810-0814)?
Weekly Report · 5d ago
Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28
NASDAQ · 08/10 10:05
Weekly Report: what happened at ENTX last week (0803-0807)?
Weekly Report · 08/10 09:07
Entera Bio GAAP EPS of -$0.14 misses by $0.06
Seeking Alpha · 08/07 21:03
Entera Bio Strengthens Finances to Advance Oral Peptide Pipeline
TipRanks · 08/07 20:58
Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028
Benzinga · 08/07 20:24
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Barchart · 08/07 15:05
Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting
Benzinga · 08/04 12:32
Weekly Report: what happened at ENTX last week (0727-0731)?
Weekly Report · 08/03 09:07
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Barchart · 07/31 15:30
Why the World’s Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX)
TipRanks · 07/30 13:30
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
PR Newswire · 07/29 19:00
Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk
Benzinga · 07/29 16:03
Entera Bio Raises $275M in Strategic Private Placement
TipRanks · 07/28 20:28
3 Top Penny Stocks to Watch Today, 7/28/2026
TipRanks · 07/28 11:30
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
NASDAQ · 07/28 03:29
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 07/27 17:06
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
Benzinga · 07/27 16:22
More
Webull provides a variety of real-time ENTX stock news. You can receive the latest news about Entera Bio Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENTX
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.